| Study Name | Principal Investigator | ||
|---|---|---|---|
| Influence of opioid analgesia on circulating tumor cells in open colorectal cancer surgery(POACC-1) | MUDr. Emil Berta |
|
|
|
Description:
Study compares the effects of three types of perioperative analgesia on the number of circulating tumor cells following radical colorectal cancer surgery. Correlations with other perioperative factors and clinical/pathological disease characteristics were assessed.Study contains three arms: morphine-based perioperative analgesia, piritramid-based perioperative analgesia and perioperative epidural analgesia containing an opioid.Baseline number of circulating tumor cells was recorded prior to surgery in a venous blood sample. Number of circulating tumor cells was measured 2 - 4 weeks after surgery in a venous blood sample. These two values were compared. Pain intensity was assessed using Numerical Rating Scale (0-10)
|
|||
| Influence of Opioid Analgesia on Circulating Tumor Cells in Laparoscopic Colorectal Cancer Surgery (POACC-2) | MUDr. Emil Berta |
|
|
|
Description:
Study compares the effects of perioperative analgesia on the number of circulating tumor cells following radical colorectal cancer surgery. Correlations with other perioperative factors and clinical/pathological disease characteristics were assessed.Study contains two arms: morphine-based perioperative analgesia and piritramid-based perioperative analgesia.Baseline number of circulating tumor cells was recorded prior to surgery in a venous blood sample. Number of circulating tumor cells was measured 2 - 4 weeks after surgery in a venous blood sample. These two values were compared. Pain intensity was assessed using Numerical Rating Scale (0-10)
|
|||
| Assessment of Multiomics Profiles in Health and Disease - Correlation With the Disease Phenotype | Marian Hajduch, MD, PhD. |
|
|
|
Description:
This study will determine reference genomic, transcriptomic, proteomic and metabolomic profiles in Czech population. Initially, there will be 1000 healthy volunteers, with the planned expansion to 10.000 participants (healthy volunteers and patients with different types of disease). Formation of the reference database of healthy volunteers and their parameters will allow a correct interpretation of the potential pathological findings in patients. It is very important to obtain healthy controls from the region of the Czech Republic, Central Europe respectively; since it is not possible to reliably compere ethnically and geographically diverse populations, which have generated in a different context and where the diseases manifest with other etiology ad phenotype. Although, in the limited measure, the similar molecular data exist in foreign databases, these are not compiled from the inhabitants of the Czech Republic, Central Europe not even from Slavic population. Study participants may volunteer for archiving of remaining biological materials for future studies.
Additional Info: This study will determine reference genomic, transcriptomic, proteomic and metabolomic profiles in Czech population and will evaluate its correlation with the disease phenotype. |
|||
| Study of resistance to cytostatic treatment in oncological patients | Ass. Prof. Marian Hajduch, MD, Ph.D. |
|
|
|
Description:
Different cytostatic substances were tested on patient biological material undergoing surgery, biopsis or other procedure for cancer diagnostics and treatment. MTT test was used to assess viability and proliferation of the cells exposed to the cytotoxic effect of various cytostatic agents. The results of the cytostatic agents with the best cytotoxic effect were reported to the treating oncologist of the patients in order to achieve the best possible treatment for the patient. Examinated biological material included at least one of the following: tissue (primary tumor/metastasis), blood, bone marrow, ascitic fluid, pleural effusion, lymph node.
|
|||
| Study of collective immunity SARS-CoV-2-CZ-Preval | Marian Hajduch, MD, PhD. |
|
|
|
Description:
The primary target parameter of the study is the estimation of the cumulative prevalence of persons who have already encountered the SARS-CoV-2 virus or have experienced the disease of COVID-19 with manifest production of antibodies, i.e. the prevalence of individuals with a past infection with the SARS-CoV-2 coronavirus, including persons with a subclinical course of the disease. Preferably venous blood was sampled and blood serum was tested using the WANTAI SARS-CoV-2 AB Rapid test for qualitative determination of antibodies against SARS-CoV-2. Participants with positive WANTAI test result provided sample of a nasopharyngeal swab. The presence of viral RNA was demonstrated by the method of quantitative polymerase chain reaction (qPCR).
Frozen blood serum from the venous blood sampling was tested using vendor1 Anti-SARS-CoV-2 ELISA test, which provided semi-quantitative in-vitro determination of human antibodies against SARS-CoV-2 virus in classes IgA and IgG. Further testing with vendor1 SARS-CoV-2 NCP ELISA test was done, which provided semi-quantitative in-vitro determination of human antibodies against SARS-CoV-2 virus in classes IgM and IgG. Also testing with vendor2 ELISA tests was done providing semi-quantitative in-vitro determination of human antibodies against SARS-CoV-2 virus in classes IgG, IgM and IgA. Also, the presence of other coronaviruses was checked.
Addressed study participants answered questions about their weight, height, smoking, household size, and occupation.
They also provided information on whether they were at work, were in quarantine from 1. March. 2020 or if they stayed abroad, if they had symptoms of a respiratory disease since 1. January. 2020.
Interpretation of results:
Vendor1: value < 0.8 negative, value ≥ 0.8 < 1.1 borderline, value ≥1.1positive
Vendor2:< 185 negative, value 185 to 210 borderline, value >210 positive
|
|||